I just realized that the only psychoactive that I haven't tried IS tilidine.
It's a really interesting compound being a opioid, a stimulant and an NMDA antagonist.
I should explain that a bit like tramadol there are four stereoisomers of tilidine but medically, the
trans pair are isolated and used.
But unlike tramdol where one stereoisomer is more or less identical to codeine, the other is a nasty thing that plays around with a person's monoamine levels. BOTH stereoisomers of tilidine are what provides that unusual mixture of activities.
I recall that for a while someone was selling nortilidine in Germany and the reviews on Land der Träume noted it was about ten times as potent as the parent drug (tilidine) i.e. about as potent as morphine as an opioid BUT also about as potent as cypenamine as a stiimulant. I really trried my best to find out how potent the NMDA activity of the two IS but the ultimate reference was to a German textbook which I couldn't access.
But if someone in Germany would like to find that reference for me, I would be really greatful.
As for tramadol, the stuff only costs $50-$100/Kg and yes, you CAN seperate the two isomers. I got to try the opioid isomer which is why I say it feels just like codeine. But if someone then performed the very simple O-demethylation - the result is something I can best describe as 'hydrocodone-like'. Not super-potent but fine it it's own way. Sure, you would only get about 400 grams of (R,R) desmethyltramadol from your Kg, but that still means something like hydrocodone for about $800/Kg.
I think I'm just surprised nobody else seems to have noticed this which I suppose makes sense if all people have ever tried is (+) tramadol and/or (+) ODMT.
BTW for the chemistry nerds - US Patent 4291059A 'Cycloaliphatic compounds, analgesic compositions thereof and method of use thereof as analgesics' is the synthesis of the reversed-ester of tilidine and I even found the contact details of the inventor (Derek P. Raynolds) so got to ask him about his work. Nice bloke. Said his design was more potent but far, far too complicated to be 'fiscally attractive' to Glaxo managers.